

02 Jun 2016 |

INFOGRAPHIC: Immuno-Oncology Targets And Deal Trends

by Mandy Jackson

Immuno-oncology R&D is surging, though most programs still are in preclinical studies or early clinical trials. Even so, dealmaking is thriving and generating lucrative terms compared with cancer deals in general as big pharma and large biotech companies look for the safest and most effective IO drug combinations.

IMMUNO-ONCOLOGY

Key Targets And Deal Facts

Immuno-oncology is one of the most active areas of drug development with companies small and large racing to bring new therapies into the clinic that address the hottest targets in cancer treatment – enthusiasm reflected by the number of firms entering into IO deals.

10 key immuno-oncology drug targets

(PD-1/PD-L1, CTLA4, GM-CSF/GM-CSFR, LAG3, TIM3, TLR, IDO, CD40, CD47 and OX40)

99

drugs and biologics
in development

therapeutic candidates:

- ✓ 5 have been approved
- ✓ 39 are in the clinic
- ✓ 55 are preclinical¹

The largest immuno-oncology category is **therapeutic candidates that target PD-1 or PD-L1** with **37** compounds in development.²



3 approved biologics **23** preclinical assets
11 in the clinic

Stages of development for all 10 drug classes reviewed³

Target	Preclinical	Phase I	Phase I/II	Phase II	Phase II/II	Phase III*
PD-1 / PD-L1 ⁽¹⁾	23	6	2	1		2
CTLA4 ⁽²⁾	5	1		1		